BTN2A1 and cardiovascular disorder: Together with an increase in reactive metabolites from BTF1 this is discussed to be a molecular key event in the AOP of COX inhibitors, leading to mitochondrial dysfunction, impairment of ATP synthesis, apoptosis, and tissue damage, and eventually causing liver and cardiovascular diseases (reviewed in [30]).